FACULTY

Full Disclosure Policy Affecting CME Activities
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Participating Faculty reported the following:

Neil M. Bressler, MD (Chair)
James P. Gills Professor of Ophthalmology
Chief, Retina Division
Wilmer Eye Institute
The Johns Hopkins University
Baltimore, Maryland
Dr Bressler reports serving as a principal investigator on grants from Allergan, Inc, Bausch & Lomb Incorporated, Bristol-Myers Squibb Company, Carl Zeiss Meditec, The EMMES Corporation, Genentech, Inc, Lumenis, Notal Vision, Novartis Pharmaceuticals Corporation, Othera Pharmaceuticals Inc, QLT Inc, Regeneron Pharmaceuticals, and Steba Biotech. Dr Bressler also reports that his spouse, Susan Bressler, MD, is a co-investigator on grants from Allergan, Inc, Bausch & Lomb Incorporated, Genentech, Inc, and Novartis Pharmaceuticals Corporation; and a consultant for Alcon Laboratories, Notal Vision, and Sightpath Medical.

Diana V. Do, MD
Assistant Professor of Ophthalmology
Wilmer Eye Institute
The Johns Hopkins University
Baltimore, Maryland
Dr Do reports serving as a principal investigator on grants from Genentech, Inc and Regeneron Pharmaceuticals. Dr Do also reports that her spouse, Quan Dong Nguyen, MD, serves on the scientific advisory board for Heidelberg.

Nancy M. Holekamp, MD
Partner, Barnes Retina Institute
Professor of Clinical Ophthalmology
Washington University School of Medicine
St. Louis, Missouri
Dr Holekamp reports serving as a principal investigator on grants from Allergan, Inc; serving as a sub-investigator on grants from Genentech, Inc; and serving as a consultant for Allergan, Inc and Genentech, Inc.

Michael S. Ip, MD
Associate Professor of Ophthalmology
University of Wisconsin
Madison, Wisconsin
Dr Ip reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grant, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

Off-Label Product Discussion
The audience is advised that presentations in this CME activity contain reference(s) to unlabeled or unapproved uses of drugs or devices:

Dr Bressler—bevacizumab and ranibizumab.
Dr Do—bevacizumab, ranibizumab, and steroids.
Dr Holekamp—bevacizumab.
Dr Ip—triamcinolone acetonide.

Return to Top

• IDENTIFY effective treatment schedules for neovascular AMD.
• APPRAISE the principles of evidence-based medicine and their application in the management of neovascular AMD.
• ASSESS the effect of VEGF blockade in retinal neovascular diseases other than AMD.
• EVALUATE the systemic safety profile of intravitreal VEGF blockade for the management of retinal neovascular diseases.

Accreditation Statement —The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement — The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

After reviewing this online activity, participants may receive credit by completing the CME test, evaluation, and receiving a score of 70% or higher.

The estimated time to complete this activity: 1.5 hours.

Release date: December 1, 2009. Expiration date: December 1, 2011.

Activity Format — Archived webcast of a symposium held at the Retina Congress 2009.

Fee Information — There is no fee for this educational activity.

DISCLAIMER
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

INTERNET CME POLICY
The Office of Continuing Medical Education (CME) at The Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. The Johns Hopkins University School of Medicine CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at The Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet-based activity. Your information will never be given to anyone outside of The Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.

Pre-Test

Conference Goals
Neil M. Bressler, MD

The Treatment Schedule: What Do We Know About Treating Monthly Versus Less Frequently
Neil M. Bressler, MD

Insight on the Principles of Evidence-Based Medicine: Do We Realize What We Do Not Know?
Michael S. Ip, MD

VEGF Blockade for the Management of Ocular Diseases Other than AMD
Diana V. Do, MD

Systemic Safety of Intravitreal Anti-VEGF
Nancy M. Holekamp, MD

Post-Test